{"entity":{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","aka":[],"tldr":"A Stanford-trained nuclear medicine doctor who leads the theranostics programme at Oregon Health & Science University and treats neuroendocrine tumour patients with radioactive peptide therapy.","summary":"Erik Mittra trained through the MD/PhD programme at Stony Brook University and completed nuclear medicine residency and PET/CT fellowship at Stanford, where he was faculty for eight years before joining Oregon Health & Science University (OHSU) in 2018. He is now Chief of Nuclear Medicine and Molecular Imaging and Director of Radiopharmaceutical Therapeutics at OHSU, running its multidisciplinary neuroendocrine tumour treatment programme.\n\nHis research focuses on peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, including as a co-author on the substudy dosimetry analysis of the pivotal NETTER-1 trial, and on 90Y radioembolisation dosimetry using fused MAA-SPECT imaging. He has published extensively on FDG and NaF PET applications in oncology dating back to his Stanford years.","asOf":"2026-09-22","links":[{"label":"OHSU provider profile","url":"https://www.ohsu.edu/providers/erik-s-mittra-md-phd"},{"label":"NETRF specialist profile","url":"https://netrf.org/specialist/erik-mittra-md-phd/"}],"tags":["neuroendocrine","PRRT","clinician"],"related":["lutathera","netter-1","radioembolisation-tare","prrt","lu-177","y-90"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Diagnostic Radiology; Chief, Nuclear Medicine and Molecular Imaging; Director, Radiopharmaceutical Therapeutics, Oregon Health & Science University","specialisms":["neuroendocrine tumour theranostics","PRRT","radioembolisation dosimetry"],"profiles":[{"label":"OHSU provider profile","url":"https://www.ohsu.edu/providers/erik-s-mittra-md-phd"}],"papers":[{"title":"Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial","journal":"Journal of Nuclear Medicine","year":2025,"doi":"10.2967/jnumed.124.268903"},{"title":"Prognostic Utility of 90Y Radioembolization Dosimetry Based on Fusion 99mTc-Macroaggregated Albumin-99mTc-Sulfur Colloid SPECT","journal":"Journal of Nuclear Medicine","year":2013,"url":"https://pubmed.ncbi.nlm.nih.gov/24136932/"}]},"route":"/people/erik-mittra/","neighbours":{"drug":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/"}],"trial":[{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/"}],"technology":[{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/"},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/"}],"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"},{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}]}}